Indivior to resolve U.S. opioid treatment marketing claims for $600 million
July 24 (Reuters) - Indivior Plc INDV.L on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.
The Slough, England-based company said it had reached the agreement with the U.S. Justice Department, the Federal Trade Commission and U.S. state attorneys general and will make the payments over a period of seven years.
As part of the deal, Indivior Solutions Inc, the subsidiary, pleaded guilty earlier in the day in federal court in Abingdon, Virginia, to one count of making a false statement relating to healthcare matters in 2012, a company spokesman said.
The Justice Department agreed to dismiss all charges against the parent company contained in an indictment unveiled in April 2019, the company said. It was one of the few corporate prosecutions related to the U.S. opioid addiction epidemic.